BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2003

View Archived Issues

Src kinase inhibitor protects mouse heart allografts

Read More

Raloxifene increases bone mineral density in Chinese women

Read More

Novel somatostatin sst2 agonists for anxiety, depression, etc. developed at Novartis

Read More

New antidepressant 5-HT receptor ligands covered by Ranbaxy patent

Read More

New orexin OX-1 antagonists, their preparation and use reported by GSK researchers

Read More

Novel cholecystokinin CCK2 antagonists and their use in gastrin-related disorders

Read More

New P2X7 receptor antagonists in early development at Pfizer

Read More

New NK1 receptor antagonists under study at Schering-Plough

Read More

Ortho-McNeil scientists prepare and test novel PDE5 inhibitors

Read More

Two series of ALK5 kinase inhibitors and their use described by GSK team

Read More

Ropinirole improves QOL in patients with restless legs syndrome

Read More

Pilot study suggests efficacy of rotigotine CDS in restless legs syndrome

Read More

Hepatobiliary tumors show encouraging response to rebeccamycin analogue in phase II trials

Read More

Positive interim data from phase II trial of Allovectin-7 reported at ASCO

Read More

News from ASCO: BMS-247550 active against breast cancer and NSCLC in phase II studies

Read More

In vitro study results for GCS-100 presented at ASCO industry sponsored satellite symposium

Read More

Ralfinamide displays excellent oral bioavailability in phase I studies

Read More

New approvals for Prempro

Read More

TheraCIM produces complete responses in head and neck cancer

Read More

Phase II SBIR grant supports discovery of novel antigens for HIV vaccines at VaxGen

Read More

HspE7 produces statistically significant results in RRP

Read More

Phase I/II trial to study CA4P plus chemotherapy in advanced ovarian cancer

Read More

MedImmune and Micromet to codevelop MT-103

Read More

Life Medical Sciences cleared to begin pivotal trial of Repel-CV

Read More

CT-2106 to advance into phase II trials

Read More

Cypress Bioscience revises milnacipran agreement with Pierre Fabre

Read More

AMG-162, a human MAb against RANKL, suppresses bone resorption in monkeys

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing